Myélome

R5458-ONC-2245

An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; anti-;BCMA x anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab,;Pomalidomide, and Dexamethasone (EPd), in Patients with Relapsed/Refractory;Multiple Myeloma (LINKER-MM3).
  • Open at Saint-Cloud since : 03/10/2024
  • Target : Adult
  • Phase : Phase III

Trial description

The primary objective of this study is to compare progression-free survival (PFS);per the Independent Review Committee (IRC) between linvoseltamab;monotherapy and EPd in randomized participants previously treated with CD38;antibodies.
Url of the trial

Main investigator